PTC Therapeutics Reports Publication of Data Demonstrating the Clinical Differentiated Benefit of Deflazacort, Says delazacort Had Notably Less Decline From Baseline In 6-Minute Walk Distance At Week 48 vs Those Treated With prednisone/prednisolone